Skip to main content
Top
Published in: Clinical Drug Investigation 6/2004

01-06-2004 | Case Reports

Improvement in Discomfort and Decreased Blood Flow Associated with Severe Arterial Wall Calcification following Etidronic Acid

Authors: Dr M. Mizuno, N. Kashima, K. Kato, A. Ito, S. Matsuo

Published in: Clinical Drug Investigation | Issue 6/2004

Login to get access

Excerpt

Long-term haemodialysis (HD) patients often have abnormal blood vessel wall calcification. Vascular wall calcification is also a major complication in end-stage renal disease (ESRD) and diabetic patients. In addition to atherosclerosis in hypertensive patients, the calcification in diabetic patients is related to glyco-oxidative modification,[1] and that in ESRD has been thought to be dependent on, for example, oxidative stress inflammation and hyperphosphotaemia.[2] Although the reason for the calcification is complicated, patients do suffer as a result of it. Abnormal vessel wall calcification is associated with cardiovascular disease, which is one of the most important predictive factors in the prognosis of HD patients. The calcification also causes severe discomfort including pain, numbness, a sensation of coldness, and intractable ulcerations in the extremities due to decreased blood flow. The degree of vascular wall calcification in HD patients is much higher than in patients of the same age without HD.[3] …
Footnotes
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
1.
go back to reference Sakata N, Takeuchi K, Noda K, et al. Calcification of the medial layer of the internal thoracic artery in diabetic patients: relevance of glycoxidation. J Vasc Res 2003; 40: 567–74PubMedCrossRef Sakata N, Takeuchi K, Noda K, et al. Calcification of the medial layer of the internal thoracic artery in diabetic patients: relevance of glycoxidation. J Vasc Res 2003; 40: 567–74PubMedCrossRef
2.
go back to reference Drueke TB, Massy ZA. Advanced oxidation protein products, parathyroid hormone and vascular calcification in uremia. Blood Purif 2002; 20: 494–7PubMedCrossRef Drueke TB, Massy ZA. Advanced oxidation protein products, parathyroid hormone and vascular calcification in uremia. Blood Purif 2002; 20: 494–7PubMedCrossRef
3.
go back to reference Qunibi WY, Nolan CA, Ayus JC. Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon. Kidney Int Suppl 2002; 82: 73–80CrossRef Qunibi WY, Nolan CA, Ayus JC. Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon. Kidney Int Suppl 2002; 82: 73–80CrossRef
4.
go back to reference Ravn P. Bisphosphonates for prevention of postmenopausal osteoporosis. Dan Med Bull 2002; 49: 1–18PubMed Ravn P. Bisphosphonates for prevention of postmenopausal osteoporosis. Dan Med Bull 2002; 49: 1–18PubMed
5.
go back to reference Miller PD. Bisphosphonates for the prevention and treatment of corticosteroid-induced osteoporosis. Osteoporos Int 2001; 12Suppl. 3: S3–10PubMedCrossRef Miller PD. Bisphosphonates for the prevention and treatment of corticosteroid-induced osteoporosis. Osteoporos Int 2001; 12Suppl. 3: S3–10PubMedCrossRef
6.
go back to reference Adamson BB, Gallacher SJ, Byars J, et al. Mineralisation defects with pamidronate therapy for Paget’s disease. Lancet 1993; 342: 1459–60PubMedCrossRef Adamson BB, Gallacher SJ, Byars J, et al. Mineralisation defects with pamidronate therapy for Paget’s disease. Lancet 1993; 342: 1459–60PubMedCrossRef
7.
go back to reference Fleish H. Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991; 42: 919–44CrossRef Fleish H. Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991; 42: 919–44CrossRef
8.
go back to reference Senaratne SG, Colston KW. The role of bisphosphonates in breast cancer: direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res 2002; 4: 18–23PubMedCrossRef Senaratne SG, Colston KW. The role of bisphosphonates in breast cancer: direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res 2002; 4: 18–23PubMedCrossRef
9.
go back to reference Miller S, Vernon-Roberts E, McClure J. Cutaneous calciphylactic reactions in the mouse and the rat and the effects of bisphosphonates on the reaction in the rat. J Pathol 1984; 142: 7–13PubMedCrossRef Miller S, Vernon-Roberts E, McClure J. Cutaneous calciphylactic reactions in the mouse and the rat and the effects of bisphosphonates on the reaction in the rat. J Pathol 1984; 142: 7–13PubMedCrossRef
10.
go back to reference Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001; 21: 817–24PubMedCrossRef Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001; 21: 817–24PubMedCrossRef
11.
go back to reference Sugiyama M, Komiya K, Inoue Y, et al. EHDP (etidronate disodium) on heterotropic ossification in hemodialysis patients. seikei Geka 1995; 46: 1754–60 Sugiyama M, Komiya K, Inoue Y, et al. EHDP (etidronate disodium) on heterotropic ossification in hemodialysis patients. seikei Geka 1995; 46: 1754–60
12.
go back to reference Lorish CD, Maisiak R. The face scale: a brief, nonverbal method for assessing patient mood. Arthritis Rheum 1986; 29: 906–9PubMedCrossRef Lorish CD, Maisiak R. The face scale: a brief, nonverbal method for assessing patient mood. Arthritis Rheum 1986; 29: 906–9PubMedCrossRef
13.
go back to reference Nitta K, Akiba T, Kawashima A, et al. Serum levels of macrophage colony-stimulating factor and aortic calcification in hemodialysis patients. Am J Nephrol 2001; 21: 465–70PubMedCrossRef Nitta K, Akiba T, Kawashima A, et al. Serum levels of macrophage colony-stimulating factor and aortic calcification in hemodialysis patients. Am J Nephrol 2001; 21: 465–70PubMedCrossRef
14.
go back to reference Aida Y, Toda Y, Shimakoshi Y, et al. Effects of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) on interleukin 1 production by macrophages. Microbiol Immunol 1986; 30: 1199–206PubMed Aida Y, Toda Y, Shimakoshi Y, et al. Effects of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) on interleukin 1 production by macrophages. Microbiol Immunol 1986; 30: 1199–206PubMed
16.
go back to reference Danenberg HD, Fishbein I, Gao J, et al. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation 2002; 106: 599–605PubMedCrossRef Danenberg HD, Fishbein I, Gao J, et al. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation 2002; 106: 599–605PubMedCrossRef
17.
go back to reference Danenberg HD, Golomb G, Groothuis A, et al. Liposomal alendronate inhibits systemic innate immunity and reduces instent neointimal hyperplasia in rabbits. Circulation 2003; 108: 2798–804PubMedCrossRef Danenberg HD, Golomb G, Groothuis A, et al. Liposomal alendronate inhibits systemic innate immunity and reduces instent neointimal hyperplasia in rabbits. Circulation 2003; 108: 2798–804PubMedCrossRef
18.
go back to reference Fogelman I, Smith L, Mazess R, et al. Absorption of oral diphosphonate in normal subjects. Clin Endocrinol 1986; 24: 57–62CrossRef Fogelman I, Smith L, Mazess R, et al. Absorption of oral diphosphonate in normal subjects. Clin Endocrinol 1986; 24: 57–62CrossRef
19.
go back to reference Reilly GC, Currey JD. The effects of damage and microcracking on the impact strength of bone. J Biomech 2000; 33: 337–43PubMedCrossRef Reilly GC, Currey JD. The effects of damage and microcracking on the impact strength of bone. J Biomech 2000; 33: 337–43PubMedCrossRef
20.
go back to reference Currey JD, Brear K, Zioupos P. The effects of ageing and changes in mineral content in degrading the toughness of human femora. J Biomech 1996; 29: 257–60PubMedCrossRef Currey JD, Brear K, Zioupos P. The effects of ageing and changes in mineral content in degrading the toughness of human femora. J Biomech 1996; 29: 257–60PubMedCrossRef
21.
go back to reference Li J, Mashiba T, Burr DB. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 2001; 69: 281–6PubMedCrossRef Li J, Mashiba T, Burr DB. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 2001; 69: 281–6PubMedCrossRef
22.
go back to reference Koivukangas A, Tuukkanen J, Hannuniemi R, et al. Effects of long-term administration of clodronate on growing rat bone. Calcif Tissue Int 2001; 69: 350–5PubMedCrossRef Koivukangas A, Tuukkanen J, Hannuniemi R, et al. Effects of long-term administration of clodronate on growing rat bone. Calcif Tissue Int 2001; 69: 350–5PubMedCrossRef
Metadata
Title
Improvement in Discomfort and Decreased Blood Flow Associated with Severe Arterial Wall Calcification following Etidronic Acid
Authors
Dr M. Mizuno
N. Kashima
K. Kato
A. Ito
S. Matsuo
Publication date
01-06-2004
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 6/2004
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.2165/00044011-200424060-00006

Other articles of this Issue 6/2004

Clinical Drug Investigation 6/2004 Go to the issue